CYP2D6与CYP2C19基因型对托莫西汀血药浓度的影响:基于治疗药物监测数据的研究
该研究基于治疗药物监测数据(n=315),发现CYP2D6中间代谢者和慢代谢者的托莫西汀剂量调整后暴露量分别比正常代谢者高1.9倍和9.6倍;无论CYP2D6基因型如何,CYP2C19*2携带者的暴露量比非携带者高1.5倍。结论提示CYP2D6基因型对托莫西汀暴露量影响大,CYP2C19*2携带者需进一步减量,建议预先进行CYP2D6/CYP2C19基因分型以个体化给药。
要点
- CYP2D6中间代谢者和慢代谢者的托莫西汀暴露量分别比正常代谢者高1.9倍和9.6倍。
- CYP2C19*2携带者托莫西汀暴露量比非携带者高1.5倍,与CYP2D6基因型无关。
- 建议预先检测CYP2D6/CYP2C19基因型以个体化调整托莫西汀剂量。
核心结论
- CYP2D6基因型对托莫西汀暴露量影响显著,CYP2C19*2携带者需进一步减量,建议预先基因分型以个体化给药并预防不良反应。
研究设计与样本
- 基于治疗药物监测服务的回顾性研究,纳入315例患者,分析血清托莫西汀浓度与CYP2D6/CYP2C19基因型的关系。
主要发现
- CYP2D6中间代谢者和慢代谢者的剂量调整后托莫西汀暴露量分别比正常代谢者高1.9倍(95%CI 1.4-2.7)和9.6倍(95%CI 5.9-16)。
- CYP2C19*2携带者的托莫西汀暴露量比非携带者高1.5倍(95%CI 1.1-2.2),无论CYP2D6基因型如何。
关键数值与推荐
- CYP2D6中间代谢者和慢代谢者的托莫西汀剂量需求分别约为正常代谢者的二分之一和十分之一。
- CYP2C19*2携带者应在此基础上进一步减少三分之一的剂量。
临床怎么用
- 临床可预先进行CYP2D6和CYP2C19基因分型,根据代谢型别个体化调整托莫西汀剂量,以降低不良反应风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Atomoxetine is mainly metabolized by CYP2D6 while CYP2C19 plays a secondary role. It is known that patients carrying genotypes encoding decreased/absent CYP2D6 metabolism obtain higher atomoxetine concentrations and are at increased risk of adverse effects. Here, we aimed to investigate the added effects of reduced-function CYP2C19 genotype on atomoxetine concentrations in real-world settings. METHODS: Serum atomoxetine concentrations and CYP2D6/2C19 genotypes were included from a therapeutic drug monitoring service. Patients were first subgrouped according to CYP2D6 encoding normal, reduced or absent CYP2D6 metabolism, referred to as normal (NM), intermediate (IM) or poor metabolizers (PM). Then, the effect of reduced-function CYP2C19 genotypes was investigated. Genotyping of the CYP2D6 nonfunctional or reduced variant alleles comprised CYP2D6*3-*6, *9-*10 and *41. For CYP2C19, the CYP2C19*2 was analysed to define metabolizer phenotype. Dose-adjusted serum atomoxetine concentration was the exposure measure. RESULTS: Using a patient cohort (n = 315), it was found that CYP2D6 IM and PM patients had 1.9-fold (95% confidence interval: 1.4-2.7) and 9.6-fold (5.9-16) higher exposure of atomoxetine compared with CYP2D6 NMs. CYP2C19*2 carriers had 1.5-fold (1.1-2.2) higher atomoxetine exposure than noncarriers regardless of CYP2D6 genotype. CONCLUSION: CYP2D6 genotype has a great impact on atomoxetine exposure, where our real-world data suggest atomoxetine dose requirements to be around half and 1/10 in CYP2D6 IM and PM vs. NM patients, respectively. When adding CYP2C19 genotype as a factor of relevance for personalized atomoxetine dosing, CYP2C19*2 carriers should further reduce the dose by a third. These findings suggest that pre-emptive CYP2D6/CYP2C19 genotyping should be performed to individualize atomoxetine dosing and prevent adverse effects.
引用
- Smith RL, Molden E, Bernard JP, et al. Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels: A study based on therapeutic drug monitoring data. Br J Clin Pharmacol. 2023. PMID: 36851891. doi:10.1111/bcp.15706
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。